# Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

> **NCT01474681** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Acute Myelocytic Leukemia
- Acute Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Myelodysplastic Syndrome
- Chronic Lymphocytic Leukemia
- Marginal Zone Lymphoma
- Follicular Lymphomas
- Large-cell Lymphoma
- Lymphoblastic Lymphoma
- Burkitt's Lymphoma
- High Grade Lymphomas
- Mantle-cell Lymphoma
- Lymphoplasmacytic Lymphoma

## Interventions

- **BIOLOGICAL:** HSC835

## Key facts

- **NCT ID:** NCT01474681
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-09
- **Primary completion:** 2016-10-03
- **Final completion:** 2016-10-03
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2020-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01474681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01474681, "Safety and Tolerability of HSC835 in Patients With Hematological Malignancies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01474681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*